[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0309491A - Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes - Google Patents

Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes

Info

Publication number
BR0309491A
BR0309491A BR0309491-0A BR0309491A BR0309491A BR 0309491 A BR0309491 A BR 0309491A BR 0309491 A BR0309491 A BR 0309491A BR 0309491 A BR0309491 A BR 0309491A
Authority
BR
Brazil
Prior art keywords
amino acid
acid sequence
protein
composition
sequence
Prior art date
Application number
BR0309491-0A
Other languages
English (en)
Inventor
Daniel Zagury
Helene Le Buanec
Bernard Bizzini
Paul Cohen
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Publication of BR0309491A publication Critical patent/BR0309491A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO DE VACINA, COMPOSIçãO IMUNOGêNICA, UTILIZAçãO DE UMA PROTEìNA E7 E ANTICORPOS NEUTRALIZANTES". A invenção trata de uma composição imunogênica ou de vacina que induz uma resposta imunitária ao encontro da proteína E7 nativa do Papillomavirus HPV-16, sem induzir simultaneamente uma imunossupressão, a dita composição compreendendo, a título de princípio ativo, uma proteína E7 mutada não imunossupressora compreendendo a sequência de aminoácidos consiste da extremidade N-terminal para a extremidade C-terminal: (i) na sequência de aminoácidos 1-19 da sequência SEQ ID N<0> 3; (ii) em uma sequência de aminoácidos possuindo (a) a substituição de pelo menos um aminoácido, em relação à sequência correspondente de aminoácidos consecutivos em relação à sequência correspondente de aminoácidos 20-29 da sequência SEQ ID N<0> 3 ou (b) a deleção de pelo menos quatro aminoácidos consecutivos em relação à sequência correspondente de aminoácidos 20-29 da sequência SEQ ID N<0> 3; e (iii) na sequência de aminoácidos 30-98 da sequência SEQ ID N<0> 3.
BR0309491-0A 2002-04-24 2003-04-04 Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes BR0309491A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0205173A FR2839072A1 (fr) 2002-04-24 2002-04-24 Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
PCT/FR2003/001082 WO2003090667A2 (fr) 2002-04-24 2003-04-04 Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16

Publications (1)

Publication Number Publication Date
BR0309491A true BR0309491A (pt) 2005-02-15

Family

ID=28799908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309491-0A BR0309491A (pt) 2002-04-24 2003-04-04 Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes

Country Status (13)

Country Link
US (1) US7314629B2 (pt)
EP (1) EP1509543B1 (pt)
JP (1) JP2005532298A (pt)
CN (1) CN1656116A (pt)
AT (1) ATE408620T1 (pt)
AU (1) AU2003249143B2 (pt)
BR (1) BR0309491A (pt)
CA (1) CA2483819C (pt)
DE (1) DE60323634D1 (pt)
DK (1) DK1509543T3 (pt)
ES (1) ES2312801T3 (pt)
FR (1) FR2839072A1 (pt)
WO (1) WO2003090667A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP5146113B2 (ja) * 2008-05-30 2013-02-20 住友電装株式会社 電気接続箱
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102482327B (zh) * 2009-06-22 2014-10-29 财团法人卫生研究院 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CN105177048B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用
CN105177047B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用
CN114075293B (zh) * 2020-08-14 2022-11-15 长沙诺盟生物医药有限公司 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2038581A1 (en) * 1990-03-20 1991-09-21 Martin Muller Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1108035B1 (en) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Treatment of cervical cancer
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Also Published As

Publication number Publication date
ATE408620T1 (de) 2008-10-15
EP1509543B1 (fr) 2008-09-17
CA2483819A1 (fr) 2003-11-06
WO2003090667A3 (fr) 2004-04-01
EP1509543A2 (fr) 2005-03-02
JP2005532298A (ja) 2005-10-27
US20060233820A1 (en) 2006-10-19
DE60323634D1 (de) 2008-10-30
AU2003249143A1 (en) 2003-11-10
US7314629B2 (en) 2008-01-01
FR2839072A1 (fr) 2003-10-31
DK1509543T3 (da) 2008-12-15
AU2003249143B2 (en) 2008-05-08
WO2003090667A2 (fr) 2003-11-06
CN1656116A (zh) 2005-08-17
ES2312801T3 (es) 2009-03-01
CA2483819C (fr) 2013-01-22

Similar Documents

Publication Publication Date Title
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
JP2018510622A5 (pt)
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
EP2360176A3 (en) Hybrid and tandem expression of neisserial derived proteins
NO20063026L (no) Antistoffer
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ATA17892000A (de) Vakzin-zusammensetzung
JP2015504052A5 (pt)
JP2017522319A5 (pt)
RU2011154363A (ru) Комбинации клад rrgb пневмококков
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
ATE466876T1 (de) Immunogene konstrukte
DK2076532T3 (da) Cytokinderivater
WO1999051188A3 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
PE20010237A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS
PE20010238A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
NZ570708A (en) Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
WO2019059709A3 (ko) Hp1404 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도
RU2002103164A (ru) Антибактериальный белок хламизин в, ген, кодирующий его, и экспрессирующая его система
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
WO2003022867A3 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
DE60022995D1 (de) Impfstoff
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.